Advertisement

Table of Contents

In This Issue

  • In This Issue
    In This Issue
    Cancer Discov February 1 2018 8 (2) 127-129; DOI:10.1158/2159-8290.CD-ITI8-2

In the Spotlight

Review

Research Briefs

  • Research Briefs | AuthorChoice
    Genomic Landscape of Cell-Free DNA in Patients with Colorectal Cancer
    John H. Strickler, Jonathan M. Loree, Leanne G. Ahronian, Aparna R. Parikh, Donna Niedzwiecki, Allan Andresson Lima Pereira, Matthew McKinney, W. Michael Korn, Chloe E. Atreya, Kimberly C. Banks, Rebecca J. Nagy, Funda Meric-Bernstam, Richard B. Lanman, AmirAli Talasaz, Igor F. Tsigelny, Ryan B. Corcoran and Scott Kopetz
    Cancer Discov February 1 2018 8 (2) 164-173; DOI:10.1158/2159-8290.CD-17-1009

    cfDNA profiling has high concordance with direct tumor sequencing in 1,397 patients with advanced colorectal cancer and uncovers EGFR ECD mutations that may drive resistance to anti-EGFR antibodies.

  • Research Briefs | AuthorChoice
    Accelerating Discovery of Functional Mutant Alleles in Cancer
    Matthew T. Chang, Tripti Shrestha Bhattarai, Alison M. Schram, Craig M. Bielski, Mark T.A. Donoghue, Philip Jonsson, Debyani Chakravarty, Sarah Phillips, Cyriac Kandoth, Alexander Penson, Alexander Gorelick, Tambudzai Shamu, Swati Patel, Christopher Harris, JianJiong Gao, Selcuk Onur Sumer, Ritika Kundra, Pedram Razavi, Bob T. Li, Dalicia N. Reales, Nicholas D. Socci, Gowtham Jayakumaran, Ahmet Zehir, Ryma Benayed, Maria E. Arcila, Sarat Chandarlapaty, Marc Ladanyi, Nikolaus Schultz, José Baselga, Michael F. Berger, Neal Rosen, David B. Solit, David M. Hyman and Barry S. Taylor
    Cancer Discov February 1 2018 8 (2) 174-183; DOI:10.1158/2159-8290.CD-17-0321

    Analysis of somatic mutational data in large patient cohorts uncovered rare hotspots that may accelerate the discovery of rare driver mutations in cancer and guide selection of targeted therapies.

Research Articles

  • Research Articles | AuthorChoice
    First-in-Class ERK1/2 Inhibitor Ulixertinib (BVD-523) in Patients with MAPK Mutant Advanced Solid Tumors: Results of a Phase I Dose-Escalation and Expansion Study
    Ryan J. Sullivan, Jeffrey R. Infante, Filip Janku, Deborah Jean Lee Wong, Jeffrey A. Sosman, Vicki Keedy, Manish R. Patel, Geoffrey I. Shapiro, James W. Mier, Anthony W. Tolcher, Andrea Wang-Gillam, Mario Sznol, Keith Flaherty, Elizabeth Buchbinder, Richard D. Carvajal, Anna M. Varghese, Mario E. Lacouture, Antoni Ribas, Sapna P. Patel, Gary A. DeCrescenzo, Caroline M. Emery, Anna L. Groover, Saurabh Saha, Mary Varterasian, Dean J. Welsch, David M. Hyman and Bob T. Li
    Cancer Discov February 1 2018 8 (2) 184-195; DOI:10.1158/2159-8290.CD-17-1119

    The ERK inhibitor ulixertinib is well tolerated and achieved partial responses in patients with NRAS-, BRAFV600-, and non-V600 BRAF-mutant advanced solid tumors in a phase I clinical trial.

  • Research Articles
    Ex Vivo Profiling of PD-1 Blockade Using Organotypic Tumor Spheroids
    Russell W. Jenkins, Amir R. Aref, Patrick H. Lizotte, Elena Ivanova, Susanna Stinson, Chensheng W. Zhou, Michaela Bowden, Jiehui Deng, Hongye Liu, Diana Miao, Meng Xiao He, William Walker, Gao Zhang, Tian Tian, Chaoran Cheng, Zhi Wei, Sangeetha Palakurthi, Mark Bittinger, Hans Vitzthum, Jong Wook Kim, Ashley Merlino, Max Quinn, Chandrasekar Venkataramani, Joshua A. Kaplan, Andrew Portell, Prafulla C. Gokhale, Bart Phillips, Alicia Smart, Asaf Rotem, Robert E. Jones, Lauren Keogh, Maria Anguiano, Lance Stapleton, Zhiheng Jia, Michal Barzily-Rokni, Israel Cañadas, Tran C. Thai, Marc R. Hammond, Raven Vlahos, Eric S. Wang, Hua Zhang, Shuai Li, Glenn J. Hanna, Wei Huang, Mai P. Hoang, Adriano Piris, Jean-Pierre Eliane, Anat O. Stemmer-Rachamimov, Lisa Cameron, Mei-Ju Su, Parin Shah, Benjamin Izar, Manisha Thakuria, Nicole R. LeBoeuf, Guilherme Rabinowits, Viswanath Gunda, Sareh Parangi, James M. Cleary, Brian C. Miller, Shunsuke Kitajima, Rohit Thummalapalli, Benchun Miao, Thanh U. Barbie, Vivek Sivathanu, Joshua Wong, William G. Richards, Raphael Bueno, Charles H. Yoon, Juan Miret, Meenhard Herlyn, Levi A. Garraway, Eliezer M. Van Allen, Gordon J. Freeman, Paul T. Kirschmeier, Jochen H. Lorch, Patrick A. Ott, F. Stephen Hodi, Keith T. Flaherty, Roger D. Kamm, Genevieve M. Boland, Kwok-Kin Wong, David Dornan, Cloud Peter Paweletz and David A. Barbie
    Cancer Discov February 1 2018 8 (2) 196-215; DOI:10.1158/2159-8290.CD-17-0833

    Mouse- and patient-derived organotypic tumor spheroids model the tumor-immune microenvironment to predict response and resistance to anti–PD-1 and evaluate potential combination therapies.

  • Research Articles
    CDK4/6 Inhibition Augments Antitumor Immunity by Enhancing T-cell Activation
    Jiehui Deng, Eric S. Wang, Russell W. Jenkins, Shuai Li, Ruben Dries, Kathleen Yates, Sandeep Chhabra, Wei Huang, Hongye Liu, Amir R. Aref, Elena Ivanova, Cloud P. Paweletz, Michaela Bowden, Chensheng W. Zhou, Grit S. Herter-Sprie, Jessica A. Sorrentino, John E. Bisi, Patrick H. Lizotte, Ashley A. Merlino, Max M. Quinn, Lauren E. Bufe, Annan Yang, Yanxi Zhang, Hua Zhang, Peng Gao, Ting Chen, Megan E. Cavanaugh, Amanda J. Rode, Eric Haines, Patrick J. Roberts, Jay C. Strum, William G. Richards, Jochen H. Lorch, Sareh Parangi, Viswanath Gunda, Genevieve M. Boland, Raphael Bueno, Sangeetha Palakurthi, Gordon J. Freeman, Jerome Ritz, W. Nicholas Haining, Norman E. Sharpless, Haribabu Arthanari, Geoffrey I. Shapiro, David A. Barbie, Nathanael S. Gray and Kwok-Kin Wong
    Cancer Discov February 1 2018 8 (2) 216-233; DOI:10.1158/2159-8290.CD-17-0915

    CDK4/6 inhibitors derepress NFAT to promote IL2 secretion, enhance T-cell activation and tumor infiltration, and cooperate with anti–PD-1 antibodies to boost antitumor immunity in vivo.

  • Research Articles
    FOXF1 Defines the Core-Regulatory Circuitry in Gastrointestinal Stromal Tumor
    Leili Ran, Yuedan Chen, Jessica Sher, Elissa W.P. Wong, Devan Murphy, Jenny Q. Zhang, Dan Li, Kemal Deniz, Inna Sirota, Zhen Cao, Shangqian Wang, Youxin Guan, Shipra Shukla, Katie Yang Li, Alan Chramiec, Yuanyuan Xie, Deyou Zheng, Richard P. Koche, Cristina R. Antonescu, Yu Chen and Ping Chi
    Cancer Discov February 1 2018 8 (2) 234-251; DOI:10.1158/2159-8290.CD-17-0468

    Gastrointestinal stromal tumors exhibit a transcriptional dependence on FOXF1, which binds enhancers to promote expression of genes, including ETV1 and KIT, required for tumor growth.

News in Brief

News in Depth

Research Watch

Back to top

Jump to

Advertisement